Michael C. VeronesiUniversity of Chicago, Radiology
Intranasal drug delivery (INDD) is an alternative to systemic administration that utilizes the direct nose-to-brain pathway within the rich perineuronal fluid spaces along olfactory and trigeminal tracts. Several drugs have already been approved for intranasal application (e.g., corticosteroids, Zomig™ for migraines, insulin, vaccines, cold remedies), and others are undergoing development and testing. Since little is known about the spatial and temporal characteristics of INDD, a method of localizing their presence in the brain of a living animal is needed. Imaging can provide in vivo tracking of drug location and concentration to understand the fate of intranasal agents. INDD to the central nervous system can be studied with in vivo imaging, providing a noninvasive, potentially repeatable, means to determine the fate of nanoparticle-containing drugs in the brain. These imaging techniques can be translated to human applications for clinical research.
Hosted by Ying Liu